Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 20, 1998

View Archived Issues

Synvisc approved for treatment of osteoarthritis in Argentina and Brazil

New imaging agents in the pipeline at Mallinckrodt

Testoderm introduced in two more important markets: China and Germany

Ribi, ATL collaborate on the development of improved allergy vaccines

Celsion ready to begin BPH treatment studies

Novel radiopharmaceutical agent available for licensing from BTG

Clinical trial results reported, development plans outlined for Aastrom stem cell therapy system

Novel CNS technology with broad potential application available from BTG

FDA awards fast track status and development grant to Surfaxin

NitroMed presents preclinical data on NO-enhanced compounds to treat male erectile dysfuntion

Statins provide protection against stroke via effects on eNOS

Good efficacy, tolerability reported for Almirall Prodesfarma's antimigraine candidate

Paclitaxel derivatives useful as antitumor agents prepared at BMS

Neurotrophic/neuroprotective agents in development at Sanofi

Isoflavone derivatives for osteoporosis with advantages over previously reported compounds

New AMPA and NMDA receptor antagonists in early research at RPR

Dopamine reuptake inhibitors in development at Pola for Parkinson's disease

First clinical findings presented for Lilly/Synaptic antimigraine drug

Taisho describes antiischemic 2-phenoxyaniline derivatives

Gene-based CF therapeutic developed by Megabios and Glaxo Wellcome proves safe in humans

Phase II trial of tgAAV-CF completed, preliminary data presented at CF conference

Positive phase I safety and efficacy results reported for INS-365

BMS acquires new antibacterial compound from Toyama

Phase I study results reported for rNAPc2; further testing of novel anticoagulant recommended

FDA Cardiovascular and Renal Drugs Advisory Committee meets this week

Yamanouchi introduces novel formulation of antiemetic drug

Ziagen to be reviewed by FDA advisory committee in early November

Glaxo Wellcome files application for new HIV protease inhibitor in Canada

ODAC votes against Warner-Lambert's prostate cancer drug

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...